In the last 30 years, limb salvage has become the standard of care in the treatment of extremity sarcoma, and amputations are rare. This has been achieved by improved diagnostics, pre- and postoperative radiotherapy, and more refined reconstructive surgical methods. Reports on functional outcome (FO) have been increasing.[@CR1]--[@CR3]

Several methods for assessing FO have been described, including subjective and objective measures.[@CR2]--[@CR4] Functional outcome measures should be valid, reliable, accurate, and clinically meaningful for the population in which the measurement is made.[@CR5],[@CR6] Consistent usage of the same measures allows benchmarking and comparison of study results over time and between research centers.

A few previous review studies have considered the topic from different perspectives. The review by Davis[@CR4] focused on FO of all extremity tissue sarcoma patients, including upper extremities and bone sarcomas. Tang et al.[@CR3] investigated quality-of-life studies in adult extremity sarcomas (also including upper extremities and bone sarcomas) and all quality-of-life studies. Furtado et al.[@CR2] reviewed physical functioning after treatment for lower- and upper-extremity sarcoma patients, including both bone and soft tissue sarcoma (STS). Only objective measures investigating postural balance, gait, and physical activity were included. All patient-reported outcome (PRO) measurement studies were excluded. Groundland et al.[@CR7] investigated pediatric patients. Wilson et al.[@CR8] studied pelvic sarcoma patients, and Winnette et al.[@CR9] investigated all patients with STS, including abdominal sarcomas. Thus, no systematic literature review has previously focused specifically on measurement of FO after surgical treatment of adult lower-extremity STS patients.

This study aimed to identify how FO has been measured in patients with surgically treated lower-extremity STS. More specifically, we sought to determine the type of methods and measures used to measure FO, whether the measures used had been tested for validity, FO for lower-extremity STS patients, and quality of the publications that report FO.

Materials and Methods {#Sec1}
=====================

Overview and Eligibility Criteria for Review {#Sec2}
--------------------------------------------

A systematic literature review was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[@CR10] A review protocol was created by the authors and is available on request.

The study included all publications concerning patients with surgically treated lower-extremity STS whose FO was measured. The exclusion criteria ruled out duplication, studies that included fewer than 20 lower-extremity STS patients (considered pilot studies),[@CR11] non-adult study populations, and publications in languages other than English.

In the current review, the measures for assessing FO were classified as "previously developed and reported measures" or "new measures developed by the authors." The "previously developed and reported measures" were defined as measures developed to assess FO and published previously. Measures, scales, or questionnaires developed by the authors themselves with the purpose to assess FO only in the reviewed article were considered "new measures developed by the authors."

To report the type of measurement applied for assessment of FO, we used the terms "patient-reported outcome," "clinician-reported outcome," "observer-reported outcome," and "performance outcome" measures.[@CR12] Patient-reported outcome (PRO) measures are based on a patient's subjective assessment. Clinician-reported outcome measures are based on evaluation by a trained health care professional. Observer-reported outcome measures are based on observation by a person other than the patient or a health professional. Performance outcome is based on measurement of performance in specific tasks and are considered objective measures.

Search Methods {#Sec3}
--------------

PubMed, Scopus, and Web of Science search engines were used for the search. All published articles were retrieved without a search time constraint on 5 May 2018. The keywords combined with Medical Subject Headings (MeSH) terms were "lower AND (limb OR limbs OR leg OR legs OR extremity OR extremities OR foot) AND sarcoma AND (functional OR functionality OR function OR outcome)."

Two authors (G.K. and M.K.) independently reviewed all titles and appropriate abstracts. All unsuitable articles were excluded by the previously mentioned exclusion criteria. A manual search was performed for all references of suitable studies by review of titles and appropriate abstracts. The included studies were reviewed and added to the final list by the set inclusion criteria. Disagreements in data extraction were resolved by discussion and consensus of the authors (G.K., M.K., K.K., J.R., and I.B.R.).

Study Data {#Sec4}
----------

Two authors (G.K. and M.K.) independently collected the following information from the included publications: study period, origin of the study, article type, anatomic location of the tumor, number of patients, age, diagnosis, measures and measurement types used for assessing FO, results of FO, and follow-up time. In case of missing data, an e-mail requesting additional information was sent to the corresponding authors.

Validity Assessment {#Sec5}
-------------------

In this review, a validated FO measure is defined as a measure that has been scientifically validated to assess FO in extremity tumor patients. A literature search was performed to detect suitable literature concerning the validity of the FO measures.

Functional Outcome {#Sec6}
------------------

In this review, FO is reported from publications that used validated FO measures, and FO results are presented as means ± standard deviations (SDs). The pooled mean and SD were calculated as a weighted average of SDs for the groups. Publications reporting FO for bone sarcoma or upper-extremity STS patients in addition to lower-extremity STS patients were included in the FO report.

Quality of Publications Assessment {#Sec7}
----------------------------------

Because the quality of a publication can be measured according to many different criteria, and because the validity of these criteria have not been determined, quality was not used to exclude studies in this review.[@CR13] The Methodological Index for Nonrandomized Studies (MINORS) quality assessment tool was used to assess the quality of publications.[@CR14] The MINORS tool is a valid instrument designed to assess the methodologic quality of nonrandomized surgical studies, either comparative or noncomparative.[@CR14] We used the MINORS tool to assess the quality of randomized controlled trials (RCTs), as has been done in previous literature.[@CR15]

The MINORS tool consists of the following 12 methodologic items for studies: a clearly stated aim, inclusion of consecutive patients, prospective collection of data, end points appropriate for the aim of the study, unbiased assessment of the study end point, follow-up period appropriate for the aim of the study, less than a 5% loss to follow-up evaluation, and prospective calculation of the study size. Additional criteria for comparative studies include adequate statistical analyses, an adequate control group, contemporary groups, and baseline equivalence of groups. The items are scored as follows; 0 (not reported), 1 (reported but inadequate), or 2 (reported and adequate). The maximum score is 16 for non-comparative studies and 24 for comparative studies.[@CR14] Results are reported as percentages from 0 to 100.

Results {#Sec8}
=======

Study Selection {#Sec9}
---------------

Details of the literature search are presented in Fig. [1](#Fig1){ref-type="fig"}. For the final review, 37 publications were selected.[@CR16]--[@CR52]Fig. 1Flow diagram showing flow of studies retrieved for systematic review of functional outcome measurement in patients with lower-extremity soft tissue sarcoma

Study Characteristics {#Sec10}
---------------------

The included studies were published between 1984 and 2018. Of the 31 retrospective and 6 prospective studies, 3 were RCTs. Of the 37 studies, 25 were cross-sectional, 7 were cohort, and 2 were case--control studies. The sample sizes of the studies ranged from 25 to 728 patients. The characteristics of the articles and the FO measurements are presented in Table [1](#Tab1){ref-type="table"}. Table 1Characteristic of the articles and functional outcome measurementsAuthorYearCountryStudy typePatientsTumor locationNumber of patientsAge (years)^a^MeasureMeasurement typeMeasurement time pointsMINORS scoreSlump et al.[@CR18]2018NET/CANRe, CSTS, free or pedicled flap reconstructionLE; UE266. LE 18159.2 ± 18.6TESS, MSTS 1987, 1993PRO, ClinROPre- and postoperatively at 9--12 months75Podleska et al.[@CR16]2017GERRe, CSSTS, previously nonresectable sarcoma, chemotherapyLE2752.7 (12--73)SMFA-DPROMinimum 5 months after surgery69Stoeckle et al.[@CR17]2017FRe, CSSTS, primary operated non-metastatic STSLE728, LE 480Median 59 (16--91)OwnClinRON/P44Saebye et al.[@CR19]2017DENRe, CSSTS, treated with first-time limb-sparing surgery without bone resectionLE; UE128, LE 90Median 61 (IQR 47--70)TESS, MSTS 1993PRO, ClinROMinimum 1 year after surgery75Harati[@CR20]2016GERRe; CSSTS, extending distally to the level of the knee jointsLE12057.4 (17--89)TESS, FF I, SF--36PROMinimum 1.3 years after surgery50Heaver et al.[@CR21]2016UKRe, CSBTS/STS/other tumors, patients underwent limb-salvage surgeryLE; UE198, LE 152LE: 52.5 (14--86)TESSPROMinimum 3 months after surgery38Chang et al.[@CR22]2016USARe, CSAll tumor types, 77 muscle only flaps, 67 MC flaps and 76 FC flapsLE;UE220. LE 156LE: 49.5 ± 18.1MSTS 1993, Karnof-sky scoreClinRON/P71Furtado et al.[@CR23]2015UKRe, CSBTS/STS, primary tumor, management by primary or secondary amputationLE100, LE STS 3753.6 (19--91)TESSPROMinimum 1 year after surgery56Rivard et al.[@CR24]2015CANPr, CSTS, primary or recurrent sarcomaLE;UE; T52, LE 3557 (24--83)TESS, MSTS 1993, SF--36PRO, ClinROPreoperatively and at 6 and 12 months postoperatively92Kang et al.[@CR25]2014S-KRe, CCSTS, flap reconstruction case-matched with primary wound-closure groupLE; UE148, LE 10448.1 ± 19.3MSTS 1993ClinRO12--15 Months after surgery71Townley et al.[@CR26]2013CANRe, CBTS/STS, preoperatively irradiated compared with non-irradiated patients46, LE 2457 ± 18TESS, MSTS 1987PRO, ClinROMinimum 1 year after surgery63Kozawa & Nishida[@CR27]2012JAPRe, CSBTS/STS, foot sarcoma. Limb salvage surgery or amputationLE31, 24 STS43 (11--76)ISOLSClinROMinimum 2 years after surgery56Friedmann et al.[@CR28]2011CANRe, CSTS, limb salvage surgery with or without adjuvant external beam radiotherapyLE; UE288. LE 20753 (16--88)MSTS 1993, TESSPRO, ClinROMinimum 1 year after surgery63Thacker et al.[@CR29]2008USARe, CSSTS, foot- and ankle-treated sarcoma patientsLE5238 (11--96)MSTS 1993ClinROMinimum 2 years after surgery63Tsukushi et al.[@CR30]2008JAPRe, CSSTS, investigation of results of arterial vs arteriovenous reconstructionLE2546 (18--77)MSTS 1993ClinROMinimum 8 months after surgery71Hoy et al.[@CR31]2006USARe, CSBTS/STS/other, sarcoma resection, limb salvage and MFR102 MFR, STS 3639 (4--90)MSTS 1993ClinROMinimum 4 months after surgery50Pardasaney et al.[@CR32]2006USARe, CSBTS/STS, amputations and limb salvageLE40849 (11--96)OwnPRO, ObsROMinimum 2 years after surgery71Pradhan et al.[@CR33]2006USA, CAN, UKRe, CSSTS, treatment of the adductor compartment tumors, 3-center comparative studyLE18456 (13--88)TESSPRON/P50Nelson et al.[@CR34]2006USARe, CSSTS, wide resection, functional restoration surgery or soft-tissue coverage with flapsLE; UE67, 48 LE52 (13--84)TESSPRON/P54Thijssens et al.[@CR35]2006NETRe, CSSTS, limb salvage vs amputationLE;UEO 39, LE 33Median 59 (15--78)SF-36^b^PROMinimum 1 year after surgery75Davis et al.[@CR36]2005CANRCTSTS, surgery and pre- or postoperative radiotherapy. Function and radiation morbidityLE; UE129, LE 100N/PMSTS 1987, TESSPRO, ClinRO2 Years88Gerrand et al.[@CR37]2004CANRe, CSTS, limb-sparing surgeryLE20754 (15--89)MSTS 1993, TESSPRO, ClinROPre- and postoperatively within 1--2 years71Rachbauer et al.[@CR38]2003AUSPr, CSSTS, marginal surgical resection, combined with both IOHDR and EBRTLE; UP; T; R; HN39, LE 29Median 58 (17--87)MSTS 1993ClinROMinimum 3 months after surgery69O'Sullivan et al.[@CR52]2002CANRCTSTS, randomized by tumor size dichotomized at 10 cm. Pre- and postoperative radiotherapy groups. Wound healingLE; UE182, LE 14554.7MSTS 1987, TESS, SF-36PRO, ClinROPreoperatively and at 6 weeks and at 3, 6, 12 and 24 months postoperatively96Davis et al.[@CR39]2002CANRCTSTS, randomized by tumor size dichotomized at 10 cm. Pre- and postoperative radiotherapy groups. Functional outcomeLE; UE185, LE 14754.7MSTS 1987, TESS, SF-36PRO, ClinROPreoperatively and at 6 weeks and 3, 6, 12 and 24 months postoperatively96Refaat et al.[@CR40]2002USARe, CSBTS/STS, limb salvage or amputationLE40855OwnPRO, ObsRON/P67Davis et al.[@CR41]2000CANRe, CSSTS, limb-preservation surgery17251MSTS 1987, 1993, TESS, SF-36PRO, ClinROMinimum 1 year after surgery56Davis et al.[@CR42]1999CANRe, CCSTS/BTS, amputation matched with limb-sparing surgeryLE3632TESS, SF-36, RNLPROMinimum 1 year after surgery75Colterjohn et al.[@CR43]1997CANRe, CSTS/fibromatosis, limb-salvage surgery for foot and ankleLE3051MSTS 1987ClinROSee comment56Pitcher & Thomas[@CR44]1994UKRe, CSSTS, "functional compartmental resection"LE24Median 47 (12--79)OwnClinROMinimum 1 month after surgery50Keus et al.[@CR45]1994NETRe, CSSTS, local treatment with curative intent and no known distant metastasesLE; UE156, LE 115Median 46 (4--89)OwnClinRON/P38Moseley[@CR46]1992USAPr, CSTS, limb salvage using neoadjuvant chemotherapy, 2 groupsLE; UE38, LE 27Median 46/54^c^OwnClinRON/P79Karasek et al.[@CR47]1992USARe, CSSTS/fibromatosisLE; UE; T41, LE 2550 (13--85)OwnClinROMinimum 7 months after surgery63Robinson et al.[@CR48]1991UKRe, CSSTS, treated with combination of surgery and radiotherapy; surgery alone; irradiation and intra-arterial doxorubicinLE; UE; P54, LE 4652 (23--82)OwnClinROMinimum 24 months after surgery31Stinson et al.[@CR49]1991USARe, CSSTS, limb-sparing surgery, radiation therapy with or without adjuvant chemotherapyLE; UE145N/POwnClinROMinimum 1 year after surgery38Talbert et al.[@CR50]1990USARe, CSSTS/unspecified, non-metastatic patientsLE; UE78, LE 39Age zones presentedOwnClinROMinimum 28 months after surgery44Lampert et al.[@CR51]1984USARe, CSSTS, wide local resection and radiation therapyLE; UP; T; HN40, 20 LE STS37 (15--67)Own, Convery scaleClinROMinimum 7 months after surgery56*NET* The Netherlands, *CAN* Canada, *GER* Germany, *F* France, *DEN* Denmark, *UK* United Kingdom, *USA* United States of America, *S-K* South Korea, *JAP* Japan, *AUS* Australia, *Re* retrospective study, *C* cohort study, *CS* cross-sectional study, *Pr* prospective study, *CC* case--control study, *RCT* randomized control trial, *STS* soft tissue sarcoma, *BTS* bone tissue sarcoma, *IOHDR* intraoperative brachytherapy, *EBRT* external beam irradiation, *LE* lower-extremity, *UE* upper extremity, *T* trunk, *R* retroperitoneum, *HN* head and neck, *P* pelvic, *MFR* muscle flap reconstructions, *TESS* Toronto extremity salvage score, *MSTS* Musculoskeletal Tumor Society, *SMFA-D* the German Short Musculoskeletal Function Assessment questionnaire, *FFI* Foot Function Index, *ISOLS* International Society Of Limb Salvage, *RNL* Reintegration to Normal Living, *PRO* patient-reported outcome, *ClinRO* clinician-reported outcome, *ObsRO* observer-reported outcome^a^Presented as mean age, unless otherwise stated^b^Measure used was RAND-36^c^Group A median, 46 years; Group B median, 54 years

Type of Measurement to Assess FO {#Sec11}
--------------------------------

A single PRO measurement was used in 8 of the 37 publications, and a clinician-reported outcome measurement was used in 17 of the 37 publications. The PRO and clinician-reported outcome measurement types were used together in 10 studies. The PRO and observer-reported outcome measures were used in two studies. No performance outcome measurement was used. All six prospective studies used clinician-reported outcome measures, and four of these also used a PRO measure (Table [2](#Tab2){ref-type="table"}).Table 2Previously developed and reported patient-reported outcome (PRO) and clinician-reported outcome (ClinRO) toolsMeasureMeasurement type*n*StudiesValidR (*n* = 31)P (*n* = 6)CS (*n* = 25)C (*n* = 7)CC (*n* = 2)RCT (*n* = 3)TESSPRO161247513+MSTS 1993ClinRO121027410+MSTS 1987ClinRO7431303+SF-36PRO7523112SMFAPRO1101000FFIPRO1101000Karnofsky scoreClinRO1101000Modified MSTS 1993 (ISOLS)ClinRO1101000RNLPRO1100010Convery scaleClinRO1101000*R* retrospective study, *P* prospective study, *CS* cross-sectional study, *C* Cohort study, *CC* Case--control study, *RCT* randomized clinical trial, *TESS* Toronto extremity salvage score, *MSTS* Musculoskeletal Tumor Society, *SMFA* Short Musculoskeletal Function Assessment, *FFI* Foot Function Index, *ISOLS* International Society Of Limb Salvage, *RNL* Reintegration to Normal Living, *PRO* patient-reported outcome, *ClinRO* clinician-reported outcome

FO Measures {#Sec12}
-----------

The majority of the publications (27/37) used previously reported measures. The most common measures were the Toronto Extremity Salvage Score (TESS) (43%, *n* = 16) and the Musculoskeletal Tumor Society (MSTS) score 1993 (32%, *n* = 12). A total of 10 different previously reported measurement tools were used (Table [2](#Tab2){ref-type="table"}). New measures developed by the authors were used in 10 publications. Of the 27 publications, one previously reported measure alone was used in 14 publications, two and three measures in 6 publications each, and four measures in 1 publication.

The RAND-36 is multidimensional PRO questionnaire identical to the Short Form 36 (SF-36) but uses a different scoring method.[@CR35] In this review, RAND-36 and SF-36 are reported together.

Timing of FO Measurement {#Sec13}
------------------------

In 4 (11%) of the 37 studies, FO was measured both pre- and postoperatively.[@CR24],[@CR37],[@CR39],[@CR52] More than one postoperative time point of measurement was used in 3 (8%) of the 37 studies.[@CR24],[@CR39],[@CR52] The time of FO measurement varied in the 31 retrospective studies. The inclusion criteria required a minimum follow-up period of 1 year in most of the studies. In 18 (58%) of the 31 retrospective studies and 12 (50%) of the 24 retrospective cross-sectional studies, the FO was measured at least 1 year after the surgery. The time point of measurement was not reported in seven studies, and additional information was not available. Additional details are presented in Table [1](#Tab1){ref-type="table"}.

Validity of the Measures {#Sec14}
------------------------

Validated FO measures were used in 23 (62%) of the 37 publications. the validated measures were the TESS[@CR1],[@CR53] and MSTS 1985[@CR4],[@CR71] and 1993[@CR1],[@CR55] (Table [2](#Tab2){ref-type="table"}). The SF-36[@CR56] validation also has been studied, but its validity as a extremity FO measure in this population is questionable.[@CR1] In addition, the validity of the Short Musculoskeletal Function Assessment (SMFA) questionnaire,[@CR57],[@CR58] the Foot Function Index (FFI),[@CR59],[@CR60] the Karnofsky score,[@CR61] and the Reintegration to Normal Living Index (RNL)[@CR62],[@CR63] measures also has been studied. However, these measures were studies in a different population of patients or as a general FO measure, or both. No studies on the validity or reliability of the modified International Society Of Limb Salvage (ISOLS)/MSTS 1993^27^ scoring system or the modified Convery scale[@CR64] were found.

Functional Outcome {#Sec15}
------------------

The TESS, MSTS 1993, or MSTS 1987 results were presented in 23 of the 37 studies. In some studies, not all the required results (mean or SD of FO results, number of lower- vs upper-extremity patients, number of STS vs other tumors) were presented. Additional information was requested from 15 corresponding authors. Five replied, with two supplying the requested additional information.

Of the 23 studies, 3 were excluded from our FO report. The reasons were as follows: only the difference in means was reported;[@CR18] several TESS scores from the same patients were included (in lower-extremity patients, a mean of 2.6 TESS results for one patient was included);[@CR21] and two studies used the same data set (a study by O'Sullivan was excluded).[@CR39],[@CR52] Means and SDs for a study by Saebye et al.[@CR19] were calculated using median and IQR results.[@CR65],[@CR66] The SDs for studies by Friedmann et al.[@CR28] and Pradhan et al.[@CR33] were approximated based on range using the range rule calculation formula (SD = \[max − min\]/4). The pre- and postoperative function results are presented in Table [3](#Tab3){ref-type="table"}. Table 3Pre- and postoperative function scores. Results of the TESS, MSTS 1993 and MSTS 1987 measuresAuthorYearLE patients (*n*)Mean TESS (SD)^a^Mean MSTS 1993 (SD)^a^Mean MSTS 1987 (SD)^b^CommentsPreoperative Rivard20153579.8 (20.6)78.8 (20.7)NAFO results including UE STS patients (*n* = 15). Results available for MSTS from 45 and for TESS from 48 patients Gerrand200420783.1 (20.1)87.9 (19.6)NAResults available for MSTS from 203 and for TESS from 172 patients Davis200214784.4 (19.0)NA26.8 (4.4)FO results including UE STS patients (*n* = 38)Postoperative Saebye20179094 (11.3)92.8 (13.6)NAFO results including UE STS patients (*n* = 38) Harati201612063.8 (17.0)NANAFO results available for 30 patients Chang2016129NA80.2 (NP)NAFO results including UE STS and other tumors. Excluded from the pooled mean and SD analysis due to missing SD data Furtado20153756.4 (23.3)NANATESS results including bone sarcoma patients (*n* = 63) Rivard20153587.1 (16.6)88.8 (11.9)NAFO results including UE STS patients (*n* = 15). Results available for MSTS from 37 and for TESS from 41 patients Kang2014104NA85.4 (13.9)NAFO result including UE STS patients (*n* = 44) Townley20132184.76 (NP)NA29.73 (NP)FO results including bone sarcoma patients. Excluded from the pooled mean and SD analysis due to missing SD data Friedmann201120489.4 (32.4--100)^c^NA32 (11--35)^c^FO results including UE STS patients (*n* = 59) Thacker200852NA83.3 (11.5)NAFO results available for 30 sarcoma patients Tsukushi200825NA70 (NP)NA Hoy200670NA90.3 (NP)NAFO results including UE STS (*n *= 6) and bone sarcoma (*n* = 39) patients Pradhan200618477 (23--100)^c^NANAFO results available for 70 patients Nelson20064885.1 (19.3)NANAFO results available for 34 patients Davis200510083.2 (21.8)NA28.9 (9.2)FO results including UE STS patients (*n* = 29) Gerrand200420782.7 (17.7)85.8 (19.0)NAResults available for MSTS from 189 and for TESS from 155 patients Rachbauer200329NA88.5 (NA)NAFO results including UE STS (*n* = 6) and other anatomic location sarcomas (*n* = 4) Davis200214780.3 (21.1)NA28.6 (7.8)FO results including UE STS patients (*n* = 38). Results available for MSTS from 163 and for TESS from 156 patients Davis200017282.7 (18.7)84.8 (20.4)30.0 (6.2) Davis19992981.6 (17.8)NANAFO results including bone sarcoma patients (*n* = 7) Colterjohn199729NANA31.4 (4.6)FO results available for 26 patients*TESS* Toronto extremity salvage score, *MSTS* Musculoskeletal Tumor Society, *LE* lower-extremity, *SD* standard deviation, *NA* not available, *NP* not presented, *UE* upper extremity, *STS* soft tissue sarcoma, *FO* functional outcome^a^Scores are presented as range of 0 (minimum) to 100 (maximum)^b^Scores are presented as range of 0 (minimum) to 35 (maximum)^c^Range (min--max)

After study selection and additional gathering of information, some studies still included upper-extremity or bone sarcoma patients.

The pooled mean and SD were calculated for TESS and MSTS 1993 results. Of 19 studies, 2 were excluded due to missing SD data. The pre- and postoperative TESS and MSTS 1993 pooled mean and SD results are presented in Fig. [2](#Fig2){ref-type="fig"}. Because not all the publications included only lower-extremity patients, TESS results for both lower- and upper-extremity STS patients were included in 2 of 3 preoperative and 5 of 12 postoperative studies. Similarly, MSTS 1993 results included both lower- and upper-extremity STS patients in 1 of 2 preoperative and 5 of 9 postoperative studies. In 3 of 17 studies, the TESS (*n* = 2) and MSTS 1993 (*n* = 1) results included other extremity tumor patients in addition to STS patients. The number of included patients is described in Table [3](#Tab3){ref-type="table"}.Fig. 2Pre- and postoperative TESS and MSTS 1993 pooled mean and SD results

The preoperative pooled mean TESS and MSTS 1993 scores were respectively 83.3 and 86.6, and the postoperative scores were respectively 83.3 and 86.2 (out of 100). In the pooled mean and SD analysis, the proportion of lower-extremity and STS patients were respectively 88% and 94%.

As a sensitivity analysis, the mean overall postoperative FO in publications including also upper-extremity or bone sarcoma patients was investigated. In publications including upper-extremity patients (7 of 17 publications), the mean overall TESS score was 86.7 (5 publications), and the MSTS score was 89.0 (5 publications). In publications that included also bone sarcomas (3 of 17 publications), the mean overall TESS score was 63.1 (2 publications), and the MSTS score was 90.3 (1 publication).

Quality of Publications {#Sec16}
-----------------------

The mean MINORS score was 62.2 (median, 62.4; range, 31--92). For the three RCTs, the respective scores were 96,[@CR39] 96,[@CR52] and 88.[@CR36] For the observational studies, the mean MINOR score was 60.2 (median, 62.5; range, 31--92). The MINORS scores for each study are presented in Table [1](#Tab1){ref-type="table"}.

Discussion {#Sec17}
==========

Based on the current systematic literature review, the most frequently used measurement types used to measure FO for surgically treated adult lower-extremity STS patients are clinician-reported outcome and PRO measurements. The most frequently used measures are the TESS and the MSTS 1993 questionnaires. Of the 10 previously reported measures, 3 were proven to provide valid scores for lower-extremity sarcoma patients. Most of the studies on lower-extremity STS FO have poor methodologic quality.

Methods and Measures of FO {#Sec18}
--------------------------

The majority of the included studies used clinician-reported outcome measurement. In the last 10 years, the use of PRO measurements has increased. Furtado et al.[@CR2] considered performance outcome an important component of FO in sarcoma patients. This clearly is a minority position in their study because no performance outcome measurement type was found. Performance outcome measurement type has been used more frequently in publications with smaller study samples.[@CR2] This may be due to the greater time requirements and equipment and personnel costs required for performance outcome measurements.[@CR2]

In the literature review of Furtado et al.[@CR2] that investigated performance outcome measurement techniques, the study size ranged from 4 to 82 patients. In the current review, one of the inclusion criteria was a minimum of 20 lower-extremity STS patients. In our study, the sample size ranged from 25 to 728 patients.

When FO is assessed in a study, it is important to avoid loss to follow-up evaluation. Loss to follow-up evaluation less than 5% is indicated in the MINORS publications' quality measurement tool as an indicator of a good-quality study.[@CR14] More important than the measurement type is that the outcome measure provide valid and reliable scores in measuring FO. However, the type of measurement should be chosen based on the objectives of the assessment, the available resources, and the aspects of FO that are of interest.

According to the current review, the TESS and MSTS 1993 questionnaires have been used most frequently. Tang et al.[@CR3] observed that the most frequently used outcome measures were the TESS, the MSTS 1987, and the SF-36. However, they observed that the TESS was used only four times, the MSTS 1987 three times, and the MSTS 1993 two times. They also found that when the MSTS was used, the 1987 version was preferred. Likewise, Groundland et al.[@CR7] found that the MSTS is the most widely used FO measure for pediatric patients after limb-preservation surgery.

Winnette et al.[@CR9] investigated patient experience with STS in all anatomic locations, including abdominal sarcomas. They found that in extremity patients, the RNL and the TESS were used three times each. The MSTS questionnaire was not presented in their review because it examined only PRO measures.

Wilson et al.[@CR8] found that the MSTS was the most frequently used measure and that the TESS was presented only once for pelvic sarcoma patients. Some studies have used both the older and newer versions of the MSTS questionnaires in the same study.[@CR18],[@CR41] Other measures such as the SF-36, the FFI, the Karnofsky score, the RNL, the SMFA, the modified MSTS 93/ISOLS, and the modified Convery scale[@CR64] have been used but much less frequently.

The MSTS 1987[@CR54] is a clinician-reported outcome assessment that evaluates seven parameters of FO (mobility, pain, stability, deformity, strength, functional, and emotional acceptance). The MSTS 1993,[@CR55] a revised version of the MSTS 1987, also is assessed by physicians. However, the MSTS 1993 is more limb-specific than the older version and includes six parameters. Pain, function, and emotional acceptance are measured for both extremities. For the lower-extremity, use of walking aids, gait, and walking are evaluated. Hand positioning, dexterity, and lifting ability are evaluated for the upper extremity.

The TESS was developed for limb sarcoma patients. As a PRO questionnaire, it measures physical disability and performance in activities of daily living.[@CR53] Janssen et al.[@CR67] found that the TESS has adequate coverage and is more reliable than the MSTS questionnaire. In addition, they found that the MSTS score is the least reliable, as indicated by a high standard error of measurement for the complete range of ability scores. Although both versions of MSTS are the most frequently used tool for assessing FO, the TESS tool is more frequently used than the two MSTS versions separately. The TESS also was developed later than the MSTS measures.[@CR53]--[@CR55]

The study by Tang et al.[@CR3] included only articles published in last 10 years. The TESS was used in four publications, the MSTS 87 in three publications, and the MSTS 93 in two publications. Because of the relatively wide use of MSTS scores, the MSTS questionnaires permit comparison of results more easily and widely than in other studies. On the other hand, the MSTS questionnaire must be completed by a clinician, thus limiting its use in studies with larger samples.

The TESS questionnaire was designed to be completed by patients and can therefore be administered by mail or electronically. This is important particularly in long-term follow-up studies. Using the TESS may avoid the need for a physician consultation, thus saving resources. Using PRO measures may make it easier for patients to participate in the study. Also, minimal clinically important differences (MCIDs) are calculated for the TESS.[@CR68] Because the MSTS measure was developed by orthopedics for surgically treated bone and soft tissue musculoskeletal tumors, it may not capture the effects of radiotherapy, chemotherapy, and other factors that also affect FO.[@CR16],[@CR36],[@CR48],[@CR49],[@CR69] Although all FO measurements have limitations, the use of standardized instruments is important. Using the TESS and MSTS measures allows for benchmarking and comparison of results with other studies.

According to the results of our literature review, most studies used only one FO measure. The use of more than one FO measure provides more precise information on FO. For example, the TESS measures activity limitations, whereas the MSTS measures impairment in extremity sarcoma patients.[@CR53],[@CR55] On the other hand, using too many time-consuming questionnaires could lead to decreased participation and loss to follow-up evaluation. In addition, using more than one FO measuring tool might not be clinically relevant.[@CR70] Study participants should be informed about the patient burden, including how many items must be completed, how long it takes to complete the questionnaires for participation in the assessment, and how many assessments are made. Questionnaires implemented in a clinical study should be carefully chosen to ensure that they are fit for the purpose.[@CR71]--[@CR74]

Most retrospective studies required a minimum follow-up period of 1 year after surgery. In addition, FO showed a decrease up to 6 months after the surgery. Beyond 1 year, FO plateaued before the scores returned to approximate pre-treatment levels 1 year after surgery.[@CR39],[@CR43],[@CR75]

Rivard et al.[@CR24] did not observe significant changes in the TESS and MSTS scores from the preoperative period to 6 months after surgery. By 12 months, the scores showed significant improvement. This is an important factor when prospective data measurement in retrospective samples is planned. In cross-sectional studies and other prospective studies, it is important to consider measuring FO at least 1 year after the surgery, in addition to other measurement time points.

Validity of Measures {#Sec19}
--------------------

The validity of a measurement tool is a multi-dimensional term. The most important measurement property is content validity. The measure should be relevant, comprehensive, and comprehensible with respect to the construct of interest and the study population.[@CR76] Structural validity is the degree to which the scores adequately reflect the dimensionality of the construct to be measured.[@CR39],[@CR77] This review considered the measure to be validated when it was tested in lower-extremity patients and reported to be a valid measurement tool.

Half of all the studies reviewed (23/37 studies) used validated tools. In 1999, Davis[@CR4] found that studies often did not use standardized, validated measures. Several measurement tools currently in routine use had been available for only a few years in 1999. Based on our review and on the previous literature, it seems that although the psychometric properties of several PRO and clinician-reported outcome measures have been extensively studied in the last decade, performance outcome measures lack quality in this field.[@CR2]

In a systematic review of objective measurement methods, Furtado et al.[@CR2] found that only a few studies investigated aspects of validity of outcome measures. For example, they found that only 1 in 18 studies investigated reliability. They concluded that this raises questions about the accuracy of the objective (in our terminology, performance outcome) measures and veracity of the results.[@CR2]

FO of Lower-Extremity STS Patients {#Sec20}
----------------------------------

The data sample in the current review included a heterogeneous group of lower-extremity STS patients. According to the current review and analysis, the postoperative FO for patients is relatively good. The mean postoperative FO measured by MSTS for patients with extremity osteosarcoma is reported to range between 40% and 76.6%.[@CR78] In pediatric bone sarcoma patients, the reported postoperative MSTS mean scores ranged from 76% to 82.5%.[@CR7] In a review of pelvic sarcoma patients, the mean MSTS score was 65%.[@CR8]

Amputation seems to decrease FO.[@CR23],[@CR78] Our FO data included relatively few articles on amputation. The MSTS 1993 FO analysis did not include any articles and the TESS analysis included only two articles on amputations.[@CR23],[@CR42] In the work of Davis et al.[@CR42] the mean TESS score for the patients with amputations was 74.5 versus 85.1 for the patients with limb-sparing procedures. In the study by Furtado et al.[@CR23] the mean TESS score was only 56.4. Han et al.[@CR78] performed a meta-analysis of osteosarcoma patients and observed that the number of amputation patients was relatively higher. The mean MSTS for the amputation patients ranged from 41.1% to 71% versus 70% to 76.6% for the patients with limb-sparing procedures, which is lower than the result of the current review. As expected, some studies show that amputation decreases FO,[@CR23],[@CR78] whereas others have failed to show a significant difference compared with limb-sparing treatment.[@CR79]--[@CR81] Based on this review, lower-extremity STS patients seem to achieve preoperative function levels postoperatively during long-term follow-up evaluation (\> 1 year).

The Quality of the Publications Reporting FO {#Sec21}
--------------------------------------------

This review included different types of studies examining varied methodologic quality. The use of the MINORS tool showed that most studies investigating lower-extremity STS FO are lacking in methodologic quality (median MINORS score, 62.4%; range, 31--92).

This is the first systematic review of FO measurement to focus on lower-extremity STS patients. The strengths of this review were the use of PRISMA guidelines and the methodologic quality assessment for this topic. The main weakness of the current review was the nonstructural search strategy for validity of FO measurement tools used. In addition, one exclusion criterion was to have "fewer than 20 lower-extremity STS patients in the study (considered a pilot study)." This might have excluded some relevant studies with small samples. Because the authors attempted to overview the existing literature on FO measurement of lower-extremity STS patients as thoroughly as possible, they included some studies containing small amounts of upper-extremity and bone sarcomas. Because the number of non--lower extremity STS patients in the reviewed studies was small (88% lower-extremity and 94% STS patients), and because the sensitivity analysis presented similar FO results for publications reporting on upper-extremity or bone sarcoma patients, the effect on FO results was small.

Conclusion {#Sec22}
==========

The most frequently used FO measurements for surgically treated adult lower-extremity STS patients are clinician-reported outcome and PRO measurements. The most widely used measure is the patient-reported TESS instrument, which has been shown to produce reliable and valid scores in assessing FO for lower-extremity sarcoma patients. Using the TESS and MSTS measures allows for benchmarking and comparison of results with other studies. Functional outcome scores seem to return to pretreatment levels 1 year after surgery. Thus, measurement of FO also should be performed at least once 1 year after surgery or later in addition to other time points. This review indicates that quality is lacking in FO studies examining surgical treatment of lower-extremity STS.

**Publisher\'s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open access funding provided by University of Helsinki including Helsinki University Central Hospital.

There are no conflicts of interest.
